BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2020 3:19:09 AM | Browse: 782 | Download: 1501
 |
Received |
|
2019-11-22 13:38 |
|
Peer-Review Started |
|
2019-11-22 13:47 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2019-12-12 00:21 |
|
Revised |
|
2020-02-19 13:09 |
|
Second Decision |
|
2020-02-27 07:33 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-02-28 06:43 |
|
Articles in Press |
|
2020-02-28 06:43 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-03-04 21:58 |
|
Typeset the Manuscript |
|
2020-03-13 08:36 |
|
Publish the Manuscript Online |
|
2020-03-26 03:19 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Retrospective Study |
| Article Title |
Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Si-Hua Dang, Qin Liu, Rong Xie, Na Shen, Shu Zhou, Wei Shi, Wen Liu, Ping Zou, Yong You and Zhao-Dong Zhong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zhao-Dong Zhong, MD, Doctor, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Hankou District, Wuhan 430030, Hubei Province, China. whxhzzd008@126.com |
| Key Words |
Graft-vs-host disease; Graft-vs-leukemia effect; Allogeneic hematopoietic stem cell transplantation; Ruxolitinib; Treatment; Antifungal drugs |
| Core Tip |
This study aimed to investigate the effect and safety of ruxolitinib add-on in the treatment of patients with steroid-refractory (SR) acute (a) and chronic (c) graft-vs-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. An important finding of this retrospective case series was that the use of ruxolitinib as a salvage therapy for SR-GVHD resulted in an overall response rate of 100% in patients with SR-aGVHD (complete response: 80%) and 82.1% in patients with SR-cGVHD (complete response: 10.7%). In addition, this was achieved with a lower dose (5-10 mg/d) of ruxolitinib than previous reports, indicating that the dose of ruxolitinib could be lowered when used in combination with antifungal drugs (CYP2C9/CYP3A4 inhibitors). |
| Publish Date |
2020-03-26 03:19 |
| Citation |
Dang SH, Liu Q, Xie R, Shen N, Zhou S, Shi W, Liu W, Zou P, You Y, Zhong ZD. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. World J Clin Cases 2020; 8(6): 1065-1073 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i6/1065.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i6.1065 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
